---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-001631"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T06:31:16.773577+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics CSO John Magnani to depart March 31; consulting through June 2024

## Summary
- Dr. John Magnani, SVP Research and CSO, employment ends March 31, 2023.
- Severance of $40,000 payable in equal installments over 3 months after separation.
- Company will pay COBRA premiums for 15 months post-separation.
- Consulting agreement from April 1, 2023 through June 30, 2024 for continued equity vesting.
- Consulting services provided at request of CEO or designee.

## SEC filing metadata
- accession: 0001558370-23-001631
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837023001631/0001558370-23-001631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837023001631/glyc-20230221x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-001631
- JSON: https://secwatch.observer/filing/0001558370-23-001631.json
- Plain text: https://secwatch.observer/filing/0001558370-23-001631.txt

## Key facts
- Executive change
  John Magnani departed as Senior Vice President of Research and Chief Scientific Officer at CRESCENT BIOPHARMA, INC..
  - Action: agreed that his employment will end
  - Role: Senior Vice President of Research and Chief Scientific Officer
  source text: On February 21, 2023, GlycoMimetics, Inc. (the “ Company ”) and Dr. John Magnani, the Company’s Senior Vice President of Research and Chief Scientific Officer, entered into an agreement (the “ Transition Agreement ”) pursuant to which the Company and Dr. Magnani have agreed that his employment with the Company will end on March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837023001631/0001558370-23-001631-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.